Evaluation of Ex Vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine

American Journal of Tropical Medicine and Hygiene

Volumn 82, Issue 5, 2010, Pages 808-813

  Kumar, Rajiv ^a   Goto, Yasuyuki ^b   Gidwani, Kamlesh ^a   Cowgill, Karen D ^b   Sundar, Shyam ^a   Reed, Steven G ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A2 ANTIGEN; CYSTEINE PROTEINASE B; GAMMA INTERFERON; INTERLEUKIN 10; K 26 ANTIGEN; KINETOPLASMID MEMBRANE PROTEIN 11; LEISHMANIA VACCINE; NUCLEOSIDASE; PARASITE ANTIGEN; RECOMBINANT ANTIGEN; STEROL 24 C METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LEISHMANIA INFANTUM; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ADULT; ANIMALS; ANTIGENS, PROTOZOAN; BIOLOGICAL ASSAY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTERFERON-GAMMA; LEISHMANIA; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PROTOZOAN VACCINES; SPLEEN;

MURINAE;

EID: 77952725081     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0341     Document Type: Article

References (23)

1. Alvar J, Yactayo S, Bern C, 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552-557.
2. Haldar JP, Ghose S, Saha KC, Ghose AC, 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702-707. (Pubitemid 14230268)
3. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr, 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 2066-2069. (Pubitemid 16155495)
4. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG, 1994. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956. (Pubitemid 24174177)
5. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa Ade A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM, 1993. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 92: 2626-2632. (Pubitemid 24006526)
6. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG, 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324-329.
7. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S, 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171. (Pubitemid 40705683)
8. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG, 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25: 7450-7458. (Pubitemid 47484004)
9. Ghosh A, Zhang WW, Matlashewski G, 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 59-66. (Pubitemid 32905314)
10. Rafati S, Zahedifard F, Nazgouee F, 2006. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 2169-2175. (Pubitemid 43255160)
11. Stager S, Smith DF, Kaye PM, 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 7064-7071. (Pubitemid 32001180)
12. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, Garcia-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E, 2005. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812-819. (Pubitemid 40165737)
13. Goto Y, Howard RF, Bhatia A, Trigo J, Nakatani M, Netto EM, Reed SG, 2009. Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol 160: 215-220.
14. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA, 1999. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 102: 249-261. (Pubitemid 29387390)
15. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA, 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850. (Pubitemid 47038186)
16. Cassatella MA, Hartman L, Perussia B, Trinchieri G, 1989. Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells. J Clin Invest 83: 1570-1579. (Pubitemid 19125762)
17. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE, Wilson ME, 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167: 893-901.
18. Kemp K, Kemp M, Kharazmi A, Ismail A, Kurtzhals JA, Hviid L, Theander TG, 1999. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 116: 500-504. (Pubitemid 29258102)
19. Stager S, Maroof A, Zubairi S, Sanos SL, Kopf M, Kaye PM, 2006. Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol 36: 1764-1771. (Pubitemid 44089043)
20. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D, 2007. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817. (Pubitemid 46631610)
21. Bhaumik S, Basu R, Sen S, Naskar K, Roy S, 2009. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27: 1306-1316.
22. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL, 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90: 4942-4946. (Pubitemid 23182951)
23. Mendonca SC, De-Luca PM, Olafson RW, Jardim A, Coutinho SG, 1994. Does lipophosphoglycan enhance the T cell-stimulatory activity of lipophosphoglycan-associated proteins? Braz J Med Biol Res 27: 553-557.